Diabetes mellitus is one of the most significant global public health challenges. According to the World Health Organization, 14% of adults aged ≥ 18 years are affected by diabetes [1], which contributes to approximately 1.6 million deaths annually [1]. In addition to its health impact, diabetes imposes a substantial economic burden on society [2–4]. For instance, the total cost of diabetes in the United States was estimated at $413 billion in 2022 [5]. Type 2 diabetes (T2DM) accounts for approximately 90% of all diagnosed diabetes cases [6]. Diabetes affects an estimated 118 million individuals in China, corresponding to 12.4% of the adult population [7]. China bears the largest burden of diabetes globally, accounting for approximately 22% of all cases worldwide [7]. Therefore, identifying modifiable risk factors and developing effective therapeutic strategies for diabetes, particularly T2DM, is of critical importance.

Triglycerides are lipid molecules composed of three fatty acids esterified to a glycerol backbone [8]. Due to variability in the fatty acid chains, triglycerides represent a diverse group of molecules. They are the primary constituents of body fat and play a central role in energy storage and supply [9].

Circulating triglyceride levels are regulated by the balance between their production—such as dietary absorption via the intestines [10] and de novo synthesis in the liver [11, 12]—and their clearance by tissues including muscle, liver, and adipose tissue [13–16]. Maintaining triglyceride homeostasis is essential for overall health [17–19]. Conversely, elevated triglyceride levels—or hypertriglyceridemia, which is defined as a triglyceride level ≥ 1.7 mmol/L [20]—are associated with increased disease risk. For example, hypertriglyceridemia has been linked to cardiovascular conditions such as hypertension [21], atherosclerosis [22], coronary heart disease [23], and stroke [24].

Emerging evidence indicates that hypertriglyceridemia is also associated with T2DM. Epidemiological studies have shown elevated triglyceride levels in individuals with T2DM [25, 26]. Furthermore, hypertriglyceridemia is associated with increased risk of diabetes diagnosis [27, 28], incidence [29–34], and mortality [28]. It is also linked to elevated cardiovascular mortality among individuals with diabetes [35]. Two large cohort studies examined the association between glucose and triglyceride levels [36, 37] and reported a positive association between fasting glucose and triglycerides in 6,093 US adults from the general population [36] and in 1,747 Chinese patients with T2DM [37]. Many mechanisms have been proposed to explain the diabetogenic effect of hypertriglyceridemia. For example, hepatic diacylglycerol accumulation increases insulin resistance via activation of protein kinase C epsilon (PKCε) [38, 39]; excessive triglycerides could block glucose oxidation via the Randle Cycle (glucose-fatty acid cycle), likely leading to insulin resistance [40]; and hypertriglyceridemia could activate apoptosis pathways, which result in β-cell dysfunction and cell death [41].

Some researchers have questioned whether individuals with normal triglyceride levels (< 1.7 mmol/L) uniformly exhibit low risk for T2DM. To date, only two studies have investigated this question [42, 43]. In one study, Beshara et al. [42] reported that individuals with higher normal triglyceride levels (1.13–1.69 mmol/L) had an increased risk of developing T2DM compared to those with levels < 1.13 mmol/L. In the second study, conducted by our research group [43], we found that normal-range triglyceride levels were positively associated with increased diabetes-related mortality in the general U.S. population, with an optimal cut-off of 1.07 mmol/L.

However, the association between triglyceride levels and T2DM prevalence has not previously been examined in individuals with normal triglyceride concentrations (< 1.7 mmol/L) in cross-sectional studies. Additionally, it remains unclear whether triglyceride levels within the normal range are associated with plasma glucose levels. This study aimed to address these knowledge gaps by examining the associations between triglyceride levels and fasting plasma glucose, and between triglyceride levels and T2DM, in a cohort of 16,706 Chinese adults with triglycerides in the normal range. We hypothesized that higher-normal triglyceride levels were positively associated with plasma glucose and T2DM risk after controlling for metabolic confounders.

This study is the first to demonstrate that triglyceride levels are positively associated with both fasting plasma glucose and T2DM diagnosis in individuals with triglycerides within the normal range. Specifically, participants with high-normal triglyceride levels (1.09–1.69 mmol/L) had 28% higher multivariate-adjusted odds of T2DM compared to those with low-normal levels (< 1.09 mmol/L).

A linear relationship was observed between triglyceride levels and fasting plasma glucose among individuals with normal triglycerides. The underlying mechanism for this finding remains unclear. Shulman hypothesized that elevated circulating triglycerides may increase intracellular concentrations of fatty acid metabolites [72]. These metabolites could activate a serine/threonine kinase cascade, leading to phosphorylation of insulin receptor substrates (IRS-1 and IRS-2), thereby reducing phosphoinositide 3-kinase (PI3K) activity [73, 74], leading to hepatic insulin resistance [75]. In addition, high triglyceride levels can lead to mitochondrial lipid overload, thereby increasing the production of reactive oxygen species and ultimately contributing to the development of metabolic disorders [76, 77]. Moreover, higher triglyceride availability may enhance β-oxidation in tissues [8, 78, 79], reducing cellular glucose consumption for energy [80] and consequently increasing blood glucose. However, reverse causality—where elevated glucose leads to higher triglyceride levels—cannot be excluded. It is worth noting that elevated blood glucose levels can promote triglyceride synthesis [81], which is subsequently packaged and secreted as very LDL (VLDL) [82].

Many reports support a causal role of elevated triglycerides in diabetes pathogenesis. In individuals without diabetes at baseline, higher fasting triglycerides have been shown to predict impaired glucose tolerance [83], impaired fasting glucose, new-onset diabetes [31–34, 42], and diabetes-related mortality [28]. Mechanistically, elevated triglycerides and their fatty acid metabolites may contribute to insulin resistance [84, 85], stimulate hepatic gluconeogenesis [86, 87], impair insulin secretion [88], and promote β-cell apoptosis [89]—all central processes in diabetes development. Furthermore, triglyceride-lowering agents have been associated with improved glycemic control. These include fibrates, which are peroxisome proliferator-activated receptor (PPAR) alpha agonists [90–93], the dual PPAR alpha/delta agonist GFT505 [94], and the diacylglycerol acyltransferase 1 inhibitor pradigastat [95]. It is also important to note that diabetes itself can elevate circulating triglyceride levels; patients with poorly controlled T2DM are more likely to exhibit hypertriglyceridemia compared to those with good glycemic control [96, 97].

However, genetic studies have yielded inconsistent findings. Triglyceride-enhancing alleles have been reported to be positively associated with [98], inversely associated with [33, 99, 100], or not associated with diabetes [101]. Notably, Klimentidis et al. [33] found that while higher baseline triglyceride levels were associated with increased diabetes incidence, triglyceride-enhancing alleles were paradoxically associated with reduced risk. These discrepancies may be due to pleiotropic effects of the selected alleles beyond triglyceride regulation.

However, no prior study has examined the association between triglycerides and plasma glucose or diabetes diagnosis specifically in individuals with normal triglyceride levels. To our knowledge, this is the first study to demonstrate that triglycerides within the normal range are positively associated with both fasting plasma glucose and T2DM diagnosis. These findings extend the known association between hypertriglyceridemia and diabetes risk to individuals with “normal” triglyceride levels (< 1.7 mmol/L).

Using ROC curve analysis, we identified an optimal triglyceride cut-off of 1.09 mmol/L for predicting T2DM diagnosis in individuals with normal triglycerides. This cut-off was validated in our cohort, as individuals with triglyceride levels between 1.09 and 1.69 mmol/L had 28% higher multivariate-adjusted odds of T2DM compared to those with levels < 1.09 mmol/L. In our previous study [43], we found that a cut-off of 1.07 mmol/L was optimal for predicting diabetes mortality, with individuals above this threshold having 43% higher odds. Similarly, Beshara et al. [42] identified 1.13 mmol/L as a useful threshold for predicting new-onset diabetes, although ROC analysis was not used. It is worth noting that the OR for the association between triglycerides and diabetes was 1.61, indicating a meaningful yet modest effect. Additionally, the AUC from the ROC analysis was 0.63, suggesting that triglyceride levels have limited discriminatory ability for identifying T2DM.

Together, these studies suggest that triglyceride concentrations near the upper end of the normal range may not be truly benign. A lower threshold may be more appropriate for assessing T2DM risk. However, further research is needed to validate this proposed cut-off.

This study has several strengths. First, the associations between triglycerides and both plasma glucose and T2DM diagnosis were adjusted for HDL and LDL cholesterol, which are common confounders [94, 102, 103]. Second, the large sample size (N = 16,706) enhances the statistical power and generalizability of the findings. In addition, this study adheres to the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. Nonetheless, this study has limitations. First, it employed a cross-sectional design; therefore, causal relationships cannot be established. Second, only a limited number of confounders were adjusted for, and other confounding factors, e.g., dietary intake, alcohol consumption, smoking, physical activity, antihypertensive medications, and use of supplements, may affect the results. Third, participants were recruited from a single hospital, which may limit the generalizability of the findings to other populations. Fourth, this study relied on single fasting glucose measurements without HbA_1c or oral glucose tolerance test confirmation. Fifth, the possibility of measurement errors cannot be excluded. Sixth, the pregnancy status of women was unknown, which may affect the results [104, 105]. Therefore, further research is warranted, including longitudinal validation, Mendelian randomization, and interventional studies to assess whether triglyceride modulation can influence diabetes incidence. In addition, whether sex and age modify the association between triglycerides and glucose needs to be investigated in the future.

It is important to note that several complementary metabolic markers are available for the assessment of metabolic status. For example, remnant cholesterol—the cholesterol component of chylomicron remnants, intermediate-density lipoproteins, and VLDLs—has been proposed as an informative marker [106, 107]. In addition, postprandial triglyceride dynamics [108, 109] and the triglyceride-glucose index have been used to provide integrated insights into lipid metabolism and insulin resistance [110].

In conclusion, this study found that higher triglyceride levels within the normal range are positively associated with fasting plasma glucose and T2DM diagnosis. Alongside previous findings [42, 43], these results support reconsideration of the current triglyceride cut-off for T2DM risk. Currently, normotriglyceridemia is defined as < 1.7 mmol/L by the 2019 European Society of Cardiology Guidelines [111] and as < 2.0 mmol/L by the American College of Cardiology/American Heart Association guidelines [112]. It is plausible that a threshold of 1.13 mmol/L (100 mg/dL) may serve as an early metabolic indicator of dysglycemia, potentially allowing for earlier intervention to reduce the risk of T2DM-related morbidity and mortality. Further research is warranted to explore this possibility.